基因多态性对儿童霉酚酸酯个体化治疗的意义  

The value of genetic polymorphisms of mycophenolate mofetil in individualized therapy

作　　者：张致庆 徐虹 ZHANG Zhiqing;XU Hong(Children’s Hospital of Fudan University, Shanghai Kidney Development ＆Pediatric Kidney Disease Research Center, Shanghai 201102, China)

机构地区：[1]复旦大学附属儿科医院肾内科上海市肾脏发育和儿童肾脏病研究中心,上海201102

出　　处：《临床儿科杂志》2018年第5期384-388,共5页Journal of Clinical Pediatrics

基　　金：2016年上海市卫生计生系统重要薄弱学科建设计划项目(儿科学)(No.2016ZB0101)

摘　　要：霉酚酸酯(MMF)在器官移植等临床治疗上发挥重要的免疫抑制作用。但由于个体间遗传背景等因素的差异,固定剂量给药并不能获得有效安全的MMF血药浓度,无法满足个体化治疗的需要,尤其在儿童中。文章重点阐述UGT、IMPDH、ABCC2、SCLO等基因多态性在儿童MMF治疗中的意义,为实现个体化精准治疗提供参考。Mycophenolate mofetil（MMF） is a cornerstone immunosuppressant in clinical therapy, such as organ transplantation. Because of the huge interindividual difference in genetic polymorphisms and some other, fixed-dose MMFtreated strategy can neither attain the targeted effective and safe MPA blood concentration nor satisfy the needs of individualized therapy, especially in children. The article reviews the value of genetic polymorphism of UGT, IMPDH, ABCC2, SLCO in MMF therapy in children to highlight its role in the precision treatment.

关 键 词：霉酚酸 基因多态性 个体化治疗 儿童 

分 类 号：R726.9[医药卫生—儿科]